Prognostic Impact of the HFA-PEFF Score in Patients with Acute Myocardial Infarction and an Intermediate to High HFA-PEFF Score.

In the case of sacubitril/valsartan, although clinical use was authorized by the FDA after further statistical analysis, the primary endpoint of the PARAGON-HF trial, according to the initial design, did not reach statistical significance.

also in 111,027 other papers